Ascendis Pharma A/S (ASND)
228.03
+0.16
(+0.07%)
USD |
NASDAQ |
Oct 05, 16:00
228.35
+0.32
(+0.14%)
After-Hours: 20:00
Ascendis Pharma Profit Margin (Quarterly) : 61.00% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.00% |
| March 31, 2026 | |
| December 31, 2025 | -13.56% |
| September 30, 2025 | -28.55% |
| June 30, 2025 | -24.58% |
| March 31, 2025 | -93.73% |
| December 31, 2024 | -22.12% |
| September 30, 2024 | -171.5% |
| June 30, 2024 | -303.9% |
| March 31, 2024 | -136.6% |
| December 31, 2023 | -63.09% |
| September 30, 2023 | -337.7% |
| June 30, 2023 | -256.2% |
| March 31, 2023 | -330.2% |
| December 31, 2022 | -905.9% |
| September 30, 2022 | -1.11K% |
| June 30, 2022 | -1.32K% |
| March 31, 2022 | -1.84K% |
| December 31, 2021 | -2.17K% |
| September 30, 2021 | -7.22K% |
| June 30, 2021 | -13.15K% |
| March 31, 2021 | -8.42K% |
| December 31, 2020 | -25.98K% |
| September 30, 2020 | -4.42K% |
| June 30, 2020 | -6.61K% |
| Date | Value |
|---|---|
| March 31, 2020 | -2.85K% |
| December 31, 2019 | -3.21K% |
| September 30, 2019 | -1.12K% |
| June 30, 2019 | -1.83K% |
| March 31, 2019 | -990.7% |
| December 31, 2018 | -304.1% |
| September 30, 2018 | -169.6K% |
| June 30, 2018 | -126.8K% |
| March 31, 2018 | -147.8K% |
| December 31, 2017 | -12.20K% |
| September 30, 2017 | -7.81K% |
| June 30, 2017 | -6.92K% |
| March 31, 2017 | -6.76K% |
| December 31, 2016 | -1.58K% |
| September 30, 2016 | -1.56K% |
| June 30, 2016 | -1.17K% |
| March 31, 2016 | -1.63K% |
| December 31, 2015 | -606.7% |
| September 30, 2015 | -345.3% |
| June 30, 2015 | -774.0% |
| March 31, 2015 | |
| December 31, 2014 | -178.3% |
| September 30, 2014 | -60.92% |
| June 30, 2014 | -54.64% |
| March 31, 2014 | -12.57% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 4.49% |
| Novo Nordisk A/S | 26.74% |
| Evaxion AS | -- |
| Genmab A/S | 26.23% |
| Zealand Pharma A/S | 87.22% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 272.7% |
| Return on Assets | 47.69% |
| Return on Invested Capital | 71.66% |
| Gross Profit Margin (Quarterly) | 90.64% |
| Operating Margin (Quarterly) | 18.39% |
| Return on Net Operating Assets | 119.6% |